Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05358548 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ATATcH Alternating Treatment Plans for Advanced Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: May 1, 2025 to May 1, 2027
    • Study completion date: Dec 1, 2025 to May 1, 2028
    v5
  2. 2 versions Re-verified since Jun 6, 2023, no change to tracked fieldsv3-v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 11
    • Start date changed from estimate of May 1, 2022 to Apr 28, 2022
    • Secondary endpoints revised (3)
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Trial Details
NCT Number NCT05358548
Lead Sponsor Rutgers, The State University of New Jersey
Conditions
(from sponsor)		 Head and Neck Cancer, Lung Cancer
Related terms Head and Neck Neoplasms, Lung Neoplasms
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov